Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
March 12, 2024 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
March 04, 2024 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...